High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation

Wille K, Sadjadian P, Becker T, Kolatzki V, Horstmann A, Fuchs C, Griesshammer M (2019)
ANNALS OF HEMATOLOGY 98(1): 93-100.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ; ; ;
Abstract / Bemerkung
Venous thromboembolism (VTE) is a major burden in patients with BCR-ABL-negative myeloproliferative neoplasms (MPN). In addition to cytoreductive treatment anticoagulation is mandatory, but optimal duration of anticoagulation is a matter of debate. In our single center study, we retrospectively included 526 MPN patients. In total, 78 of 526 MPN patients (14.8%) had 99 MPN-associated VTE. Median age at first VTE was 52.5years (range 23-81). During a study period of 3497years, a VTE event rate of 1.7% per patient/year was detected. 38.4% (38/99) of all VTEs appeared before or at MPN diagnosis and 55.6% (55/99) occurred at uncommon sites like splanchnic or cerebral veins. MPN patients with VTEs were significantly more female (p=0.028), JAK2 positive (p=0.018), or had a polycythemia vera (p=0.009). MPN patients without VTEs were more often CALR positive (p=0.023). Total study period after first VTE was 336years with 20 VTE recurrences accounting for a recurrence rate of 6% per patient/year. In 36 of 71 MPN patients with anticoagulation therapy after first VTE event (50.7%), prophylactic anticoagulation was terminated after a median time of 6months (range 1-61); 13 of those 36 patients (36.1%) had a VTE recurrence after a median of 13months (range 4-168). In contrast, only three of 35 (8.6%) patients with ongoing anticoagulation had a VTE recurrence (p=0.0127). Thus, termination of prophylactic anticoagulation was associated with a significantly higher risk of VTE recurrence. Our data suggest that in MPN patients with VTE, a prolonged duration of anticoagulation may be beneficial.
Erscheinungsjahr
Zeitschriftentitel
ANNALS OF HEMATOLOGY
Band
98
Ausgabe
1
Seite(n)
93-100
ISSN
eISSN
PUB-ID

Zitieren

Wille K, Sadjadian P, Becker T, et al. High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. ANNALS OF HEMATOLOGY. 2019;98(1):93-100.
Wille, K., Sadjadian, P., Becker, T., Kolatzki, V., Horstmann, A., Fuchs, C., & Griesshammer, M. (2019). High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. ANNALS OF HEMATOLOGY, 98(1), 93-100. doi:10.1007/s00277-018-3483-6
Wille, K., Sadjadian, P., Becker, T., Kolatzki, V., Horstmann, A., Fuchs, C., and Griesshammer, M. (2019). High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. ANNALS OF HEMATOLOGY 98, 93-100.
Wille, K., et al., 2019. High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. ANNALS OF HEMATOLOGY, 98(1), p 93-100.
K. Wille, et al., “High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation”, ANNALS OF HEMATOLOGY, vol. 98, 2019, pp. 93-100.
Wille, K., Sadjadian, P., Becker, T., Kolatzki, V., Horstmann, A., Fuchs, C., Griesshammer, M.: High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. ANNALS OF HEMATOLOGY. 98, 93-100 (2019).
Wille, Kai, Sadjadian, Parvis, Becker, Tatjana, Kolatzki, Vera, Horstmann, Anette, Fuchs, Christiane, and Griesshammer, Martin. “High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation”. ANNALS OF HEMATOLOGY 98.1 (2019): 93-100.

33 References

Daten bereitgestellt von Europe PubMed Central.

Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study.
Hultcrantz M, Wilkes SR, Kristinsson SY, Andersson TM, Derolf AR, Eloranta S, Samuelsson J, Landgren O, Dickman PW, Lambert PC, Bjorkholm M., J. Clin. Oncol. 33(20), 2015
PMID: 26033810
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.
Kaifie A, Kirschner M, Wolf D, Maintz C, Hanel M, Gattermann N, Gokkurt E, Platzbecker U, Hollburg W, Gothert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berdel WE, Brummendorf TH, Koschmieder S; Study Alliance Leukemia (SAL)., J Hematol Oncol 9(), 2016
PMID: 26944254
Efficacy and safety of low-dose aspirin in polycythemia vera.
Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators., N. Engl. J. Med. 350(2), 2004
PMID: 14711910
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study., N. Engl. J. Med. 353(1), 2005
PMID: 16000354
Venous thromboembolism: epidemiology and magnitude of the problem.
Goldhaber SZ., Best Pract Res Clin Haematol 25(3), 2012
PMID: 22959540
Splanchnic vein thrombosis in myeloproliferative neoplasms.
Sekhar M, McVinnie K, Burroughs AK., Br. J. Haematol. 162(6), 2013
PMID: 23855810
Splanchnic vein thrombosis: clinical presentation, risk factors and treatment.
De Stefano V, Martinelli I., Intern Emerg Med 5(6), 2010
PMID: 20532730
Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
Bertozzi I, Bogoni G, Biagetti G, Duner E, Lombardi AM, Fabris F, Randi ML., Ann. Hematol. 96(8), 2017
PMID: 28585070
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists.
De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larran A, Iurlo A, Randi ML, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Rossi E, Betti S, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola R, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Sant'Antonio E, Vannucchi AM, Barbui T., Leukemia 30(10), 2016
PMID: 27113812
Oral rivaroxaban for symptomatic venous thromboembolism.
S, N. Engl. J. Med. 363(26), 2010
PMID: 21128814
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia.
Hernandez-Boluda JC, Arellano-Rodrigo E, Cervantes F, Alvarez-Larran A, Gomez M, Barba P, Mata MI, Gonzalez-Porras JR, Ferrer-Marin F, Garcia-Gutierrez V, Magro E, Moreno M, Kerguelen A, Perez-Encinas M, Estrada N, Ayala R, Besses C, Pereira A; Grupo Espanol de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)., Ann. Hematol. 94(6), 2015
PMID: 25680896
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Mico C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, Leone G, Barbui T; GIMEMA CMD-Working Party., Haematologica 93(3), 2008
PMID: 18268279
Epidemiology and risk factors for venous thrombosis.
Cushman M., Semin. Hematol. 44(2), 2007
PMID: 17433897
Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (OGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
Kreher S, Ochsenreither S, Trappe RU, Pabinger I, Bergmann F, Petrides PE, Koschmieder S, Matzdorff A, Tiede A, Griesshammer M, Riess H; Haemostasis Working Party of the German Society of Hematology and Oncology; Austrian Society of Hematology and Oncology; Society of Thrombosis and Haemostasis Research., Ann. Hematol. 93(12), 2014
PMID: 25307456
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.
Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T., J. Clin. Oncol. 23(10), 2005
PMID: 15710945
Cardiovascular events and intensity of treatment in polycythemia vera.
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group, Barbui T, Finazzi G, Marchioli R, Specchia G, Masciulli A, Marfisi RM, Cavazzina R, Scarano M, D'Amico A, Ferri B, Guido C, Marfisi L, Pera C, Polidoro A, Marchioli R, Sacco M, Levantesi G, Tognoni G, Barosi G, Carobbio A, Leoni P, Scortechini AR, Mulattieri S, Tomassetti S, Honorati E, Specchia G, Ricco A, Albano F, Pastore D, Carluccio P, Mazzone AM, Rossi AR, Finazzi G, Finazzi MC, Delaini F, Falanga A, Rambaldi A, Quarta G, Guaragna G, Giannotta A, Angelucci E, Usala E, Simula MP, Pilo F, Cacciola R, Cacciola E, Pezzella F, Seria E, Di Francesco E, Rapezzi D, Gallamini A, Bertolotti L, Vannucchi AM, Antonioli E, Guglielmelli P, Pieri L, Susini MC, Bartalucci N, Bosi A, Musolino C, D'Angelo A, Centorrino R, Gerace D, Allegra A, Iurlo A, Cortelezzi A, De Philippis C, Ferretti E, Ciceri F, Claudiani S, Lunghi F, Malato S, Trinca S, Pogliani EM, Belotti A, Lanzi E, Elli EM, Gaidano G, Lunghi M, Deambrogi C, Rossi D, Saglio G, Cilloni D, Rotolo A, Zanone C, Randi ML, Bertozzi I, Tezza F, Aneloni V, Siragusa S, Quintini G, Saccullo G, Caracciolo C, Cazzola M, Casetti I, Elena C, Landini B, Rumi E, Visani G, Barulli S, Guiducci B, Lucesole M, Malerba L, Isidori A, Santini S, Grossi A, De Stefanis M, Biagioni C, Tieghi A, Merli F, Imovilli A, Codeluppi K, Rubagotti S, Romano N, Bonini A, Bellesia E, Musto P, Martorelli MC, Villani O, Zifarone E, Zonno A, Santopietro V, De Stefano V, Za T, Rossi E, Ciminello AM, Betti S, Alimena G, Latagliata R, Tafuri A, Breccia M, Carmosino I, Spadea A, Pisani F, Romano A, D'Andrea M, Cascavilla N, Nobile M, Mantuano FS, Rossi G, Tricarico M, Rodeghiero F, Ruggeri M, Bedin F, Lissandrini L, Finotto S., N. Engl. J. Med. 368(1), 2012
PMID: 23216616
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; ANAHYDRET Study Group, Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE, Gastl G, Gisslinger B, Muellauer L, Schlogl E, Indrak K, Pytlik R, Briere J, Kiladjian JJ, Beykirch M, Gaede B, Griesshammer M, Herbrik-Zipp M, Hurtz HJ, Jacobs G, Jacki SH, Keilholz U, Mezger J, Schlag P, Schriever F, Masszi T, Sacchi S, Grinipti R, Tavoriene I, Dmoszynska A, Hellman A, Jedrzejczak WW, Robak T, Skotnicki A, Goh YT, Cernelc P., Blood 121(10), 2013
PMID: 23315161
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.
Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T., Blood 117(22), 2011
PMID: 21490340
Thrombosis in primary myelofibrosis: incidence and risk factors.
Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larran A, Rambaldi A, Finazzi G, Barosi G., Blood 115(4), 2009
PMID: 19965680
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.
Kaifie A, Kirschner M, Wolf D, Maintz C, Hanel M, Gattermann N, Gokkurt E, Platzbecker U, Hollburg W, Gothert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berdel WE, Brummendorf TH, Koschmieder S; Study Alliance Leukemia (SAL)., J Hematol Oncol 9(), 2016
PMID: 26944254
Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution.
Cervantes F, Alvarez-Larran A, Arellano-Rodrigo E, Granell M, Domingo A, Montserrat E., Leukemia 20(1), 2006
PMID: 16307011
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients.
De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larran A, Iurlo A, Randi ML, Pieri L, Rossi E, Guglielmelli P, Betti S, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola E, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Barbui T., Blood Cancer J 6(11), 2016
PMID: 27813534
Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients.
Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, Tefferi A., Am. J. Hematol. 91(4), 2016
PMID: 26799697
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.
Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M; Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators., N. Engl. J. Med. 349(7), 2003
PMID: 12917299
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.
Finazzi MC, Carobbio A, Cervantes F, Isola IM, Vannucchi AM, Guglielmelli P, Rambaldi A, Finazzi G, Barosi G, Barbui T., Leukemia 29(5), 2014
PMID: 25482134

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 30155552
PubMed | Europe PMC

Suchen in

Google Scholar